Adrenomyeloneuropathy (AMN) Epidemiology Insights Highlight Nearly 3,500 Diagnosed Prevalent Cases Across the 7MM in 2024

DelveInsight's "Adrenomyeloneuropathy (AMN) Epidemiology Report" delivers an in-depth understanding of AMN, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Explore the intricate details of the Adrenomyeloneuropathy (AMN) Epidemiology Report @ https://www.delveinsight.com/report-store/adrenomyeloneuropathy-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Key Takeaways from the Adrenomyeloneuropathy (AMN) Epidemiology Report
• In 2024, the total diagnosed prevalent cases of AMN were approximately 3,500 cases in the 7MM.
• In the 7MM, the highest number of diagnosed prevalent cases of AMN were observed in the US with approximately 1,000 cases.
• In 2024, EU4 and the UK accounted for approximately 2,000 cases of AMN, in which Germany accounted for the highest percentage of diagnosed prevalent cases while Italy accounted for the lowest.
• In 2024, Japan accounted for approximately 500 cases of AMN.
• In EU4 and the UK, Germany accounted for the highest number (~500 cases) of diagnosed prevalent cases in 2024.
• In 2024, Italy reported the lowest cases of AMN, approximately 250, in the 7MM.

Download the report to understand which factors are driving Adrenomyeloneuropathy (AMN) epidemiology trends @ https://www.delveinsight.com/sample-request/adrenomyeloneuropathy-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

What is Adrenomyeloneuropathy (AMN)?
Adrenoleukodystrophy (ALD), also called X-linked ALD (X-ALD), is a rare genetic disorder characterized by the impaired metabolism of very long-chain fatty acids (VLCFAs), leading to their accumulation in various tissues, especially the nervous system and adrenal glands. AMN is the most prevalent form of ALD, primarily affecting adult men. It typically begins with a gradual onset of leg stiffness and weakness, difficulty in walking, and pain or discomfort due to nerve damage. Additional symptoms may include bladder and bowel dysfunction, as well as sexual dysfunction. Unlike cerebral ALD, AMN tends to progress more slowly and is less likely to cause severe cognitive decline, though it can result in significant disability over time.

AMN is caused by genetic mutations in the ABCD1 gene, which provides the instructions to produce the adrenoleukodystrophy protein (ALDP), responsible for transporting very long-chain fatty acids (VLCFA) to peroxisomes, specialized compartments in cells where these molecules are broken down. AMN can be inherited from parent to child, following an X-linked recessive pattern. Symptoms vary greatly from person to person, with common signs including leg stiffness, weakness, and pain that often develop slowly and may intensify over time.

Adrenomyeloneuropathy (AMN) Diagnosis
Diagnosing AMN requires a combination of biochemical, genetic, and imaging tests to confirm the condition and assess the extent of disease involvement. Since AMN symptoms can overlap with other neurological and metabolic disorders, a structured diagnostic approach is essential to ensure early and accurate detection. Adrenomyeloneuropathy (AMN) is a rare neurodegenerative disorder that can take years to diagnose accurately, as many primary care providers may not be familiar with it, and patients often need to consult multiple specialists before receiving a definitive diagnosis. Proactive engagement with healthcare providers is essential to help shorten the diagnostic timeline.

Download the report to understand which factors are driving Adrenomyeloneuropathy (AMN) epidemiology trends @ https://www.delveinsight.com/report-store/adrenomyeloneuropathy-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Adrenomyeloneuropathy (AMN) Epidemiology Segmentation in the 7MM
• Total Diagnosed Prevalent Cases of Adrenomyeloneuropathy (AMN)
• Total Treated Cases of Adrenomyeloneuropathy (AMN)

Adrenomyeloneuropathy (AMN) Epidemiology Insights
In 2024, the total diagnosed prevalent cases of AMN were approximately 3,500 in the 7MM, with the US recording the highest burden at approximately 1,000 diagnosed prevalent cases. Across EU4 and the UK, diagnosed prevalent cases totaled approximately 2,000 in 2024, with Germany accounting for the highest share at approximately 500 cases and Italy reporting the lowest at approximately 250 cases. Japan accounted for approximately 500 diagnosed prevalent cases of AMN in 2024.

Scope of the Adrenomyeloneuropathy (AMN) Epidemiology Report
• Study Period: 2021-2034
• Forecast Period: 2025-2034
• Geographies Covered: The United States; EU4 (Germany, France, Italy, and Spain) and the United Kingdom; Japan
• Adrenomyeloneuropathy (AMN) Epidemiology Segmented by Total Diagnosed Prevalent Cases and Total Treated Cases
• Ten-year Forecast and Country-wise Epidemiology Distribution
• Comprehensive Insight into Current Diagnostic Practices and Challenges in Establishing Diagnosis

To know more about Adrenomyeloneuropathy (AMN) epidemiology trends, visit @ https://www.delveinsight.com/sample-request/adrenomyeloneuropathy-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Table of Content
1. Key Insights
2. Report Introduction
3. Adrenomyeloneuropathy (AMN) Epidemiology Overview at a Glance
4. Executive Summary of Adrenomyeloneuropathy (AMN)
5. Epidemiology Forecast Methodology
6. Disease Background and Overview
7. Epidemiology and Patient Population
8. Appendix
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight

Company Name: DelveInsight Business Research LLP
Contact Person: Abhishek kumar
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com

About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.